Multicentric, Non-Inferiority, Randomized, Non-Blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-Infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal).

Trial Profile

Multicentric, Non-Inferiority, Randomized, Non-Blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-Infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Darunavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Abacavir; Didanosine; Lopinavir/ritonavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms 2LADY
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 05 Apr 2015 Planned End Date changed from 1 Jul 2014 to 1 Sep 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top